Leqembi clinical trials are still ongoing, and participants have a 50/50 chance of receiving the $26,500-per-year drug for free. The other half will receive…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
How do clinical trials work? Are they free? Am I eligible? Being Patient answers readers’ most frequently asked questions about clinical trials for Alzheimer’s…
AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101. The majority of experimental Alzheimer’s drugs are being designed…
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
Longeveron’s investigational early-stage Alzheimer’s drug Lomecel-B, made from donated bone marrow, is enrolling participants for a clinical trial. Scientists have faced obstacle after obstacle…
Lack of diversity in clinical trials for Alzheimer’s and other diseases is hurting research, experts say. New data offers some solutions. New research presented…